Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Si Y, Peng W, Liu L, Tan M, Wang S, Zheng C, Peng P, Xia Q, Zheng K, Liu X, Liu Y, Tan Y. Brevilin A induces mitochondrial dysfunction and endoplasmic reticulum stress in breast cancer through WWP2-mediated KLF5 degradation. Chin J Nat Med. 2026 Nov; 24(11):1379-1391.
-
Fritz AJ, Greenyer H, Dillac L, Chavarkar P, Neeli A, Ullah R, Malik M, Hong D, Toor R, Pacht E, Person AG, Zotkin G, Korzec S, Gao C, Abuorquob A, Warren J, Del Porto J, Perelman J, Montecino M, Lian JB, Van Wijnen A, Heath J, Ghule P, Frietze S, Zaidi SK, Stengel K, Hiebert S, Reed K, Misteli T, Gordon JA, Stein JL, Stein GS. Acute degron-mediated RUNX1 loss reprograms enhancer activity associated with epithelial destabilization and initiation of cancer hallmarks. Cell Rep. 2026 Oct 27; 45(10):118101.
-
Herrera K, Mitra S, Sun Y, Lucero K, Singh KA, Chen K, Takizawa M, Shah GL, Giralt S, Park JH, Usmani SZ, Chaligne R, de Stanchina E, Mailankody S, Leslie CS, Perica K. The EF1? promoter of cilta-cel drives a highly effective GZMK+ transcriptional program. Nat Commun. 2026 09 19; 17(1).
-
Gani M, Agostini F, Secco L, De Pino L, Picco R, Licastro D, Tolotto V, D'Este F, Choudhary H, Ferino A, Rapozzi V, Barasa L, Ohta Y, Nakagawa H, Sgarra R, Thompson PR, Xodo LE, Di Giorgio E. PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors. Cell Rep. 2026 Oct 27; 45(10):118016.
-
Johnson MA, Varanasi SK, Mangalhara KC, Lande K, Rojas GR, Esparza-Moltó PB, Reynolds MB, Olliffe N, Wessendorf-Rodriguez K, Ghosh S, Chen D, Moyzis AG, Donnelly MP, Chinn R, Xu Z, Grae KJ, Tripple V, LaPorta MA, Metallo CM, Hargreaves DC, Kaech SM, Shadel GS. Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science. 2026 Sep 10; 393(6816):1107-1116.
-
Zhang S, Li M, Liu M, Patten ND, Labaf M, Jeong J, Sun H, Lourie J, Zou K, Patalano S, Mulhearn MJ, Macoska JA, Gao S, Andreotti R, Pennuto M, Han D, Balk SP, Cai C. Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer. Proc Natl Acad Sci U S A. 2026 Sep 15; 123(37):e2534152123.
-
Ye T, Alamgir A, Robertus CM, Colina D, Monticello C, Donahue TC, Bandi C, Hong L, Vincoff S, Goel S, Lam K, Heyes J, Putnam D, Alabi CA, Chatterjee P, DeLisa MP. Programmable protein degraders enable selective knockdown of pathogenic ?-catenin subpopulations in vitro and in vivo. Sci Adv. 2026 Aug 28; 12(35):eaec8271.
-
Lero MW, Morgan JS, Card MA, Zhu LJ, Li J, Li R, Bui QT, Mohlmann E, Goel HL, Shaw LM. Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer. J Biol Chem. 2026 Oct; 302(10):113426.
-
Yang L, Raza F, Song J, Xi X, Yang S, Xiao H, Jiang L, Chen W, Zhong J, Qiu M, Su J. Copper arsenite-loaded hydrogel for breast cancer therapy via cuproptosis-induced immunity synergized with arsenic chemotherapy. Colloids Surf B Biointerfaces. 2026 Dec; 268(Pt 1):116023.
-
Yuan Y, Lu Y, Han X, Zhang Y, Guo Q, Yao H, Yu Q, Zhou M, Huang X, Wang H, Niu M, Yin J, Rong H, Huang L, Li X, Xu S, Zheng L. ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression. Exp Mol Med. 2026 Jul; 58(7):2202-2222.